Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests
Journal of Clinical MicrobiologyPublished 1 March 2000Open access
Linda L. Jagodzinski, Debra L. Wiggins, Joshua L. McManis, Sandra Emery, Julie Overbaugh, Merlin L. Robb
Citations63
SJR quartileQ1
SJR score1.88
SNIP1.68
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The performances of six quantitative viral RNA tests are described, for the first time, with calibrated viral isolates of diverse subtypes of HIV-1 subtypes.
Abstract
Optimal management of human immunodeficiency virus type 1 (HIV-1) disease requires accurate quantitation of viral RNA concentrations in plasma. Evidence for increasing geographic intermixing of HIV-1 subtypes makes equivalent quantitation of all subtypes essential. The performances of six quantitative viral RNA tests are described, for the first time, with calibrated viral isolates of diverse subtypes.
Keywords
Immunology and MicrobiologyMedicine
SciencePrognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
2,705 Citations1996John W. Mellors, Charles R. Rinaldo +4 more
Plasma viral load was a better predictor of progression to AIDS and death than was the number of CD4+ T cells, and the risk of acquired immunodeficiency syndrome (AIDS) and death in study subjects was directly related to plasma viral load at study entry.
Annals of Internal MedicineQuantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion
940 Citations1995John W. Mellors, Lawrence A. Kingsley +5 more
The objective was to compare plasma HIV-1 RNA with determinations of serum p24 antigen, neopterin, and 2-microglobulin levels and CD4+ T-cell counts as predictors of outcome in a cohort of homosexual men with documented HIV- 1 seroconversion.
ScienceDirect Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects
784 Citations1996Kenji Harada, O. Kamimura +4 more
The microscopic mechanism of the matching effect in a superconductor, which manifested itself as the production of peaks or cusps in the critical current at specific values of the applied magnetic field, was investigated with Lorentz microscopy to allow direct observation of the behavior of vortices in a niobium thin film.
New England Journal of MedicineChanges in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
734 Citations1996William A. O’Brien, Pamela Hartigan +7 more
Treatment-induced changes in the plasma HIV-1 RNA level and the CD4+ lymphocyte count are valid predictors of the clinical progression of HIV-related disease and can be used to assess the efficacy of zidovudine and possibly other antiretroviral drugs as well.
Journal of VirologyA new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon
386 Citations1994Lutz Gürtler, Pierre Hauser +6 more
MVP-5180 constitutes a group subtype O of the most divergent HIV-1 isolates yet identified and is important for understanding the natural history of the primate immunodeficiency viruses and for the development of vaccines and diagnostics.
Journal of VirologyGenomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate
232 Citations1994Marleen Vanden Haesevelde, J.-L. Decourt +5 more
Analysis of the complete sequence of a human immunodeficiency virus (HIV) isolate (Ant70) obtained from a Cameroonian patient indicates that this virus is the most divergent strain within the HIV-1 family hitherto described.
Human retroviruses and AIDS 1997
225 Citations1997Bette Korber, Brian Foley +1 more
This compendium is the result of an effort to compile, organize, and rapidly publish as much relevant molecular data concerning the human immunodeficiency viruses (HIV) and related retroviruses as possible.
AIDSSubtype-specific problems with quantification of plasma HIV-1 RNA
156 Citations1997Annette Alaeus, Knut Lidman +2 more
The HIV monitor assay and the NASBA assay appear unable to accurately quantify HIV‐1 RNA levels in plasma samples from many subtype‐A‐infected individuals and these problems are likely to be due to primer mismatches and they limit the possibility of using these assays for routine monitoring of HIV‐ 1‐infecting individuals in many parts of the world.
Annals of Internal MedicineReport of the NIH Panel To Define Principles of Therapy of HIV Infection*
153 Citations1998
The goal of this supplement is to assist clinicians and patients in making informed decisions about treatment options so that effective antiretroviral therapy is introduced before extensive immune system damage has occurred and viral load monitoring is used as an essential tool in determining an HIV-infected person's risk for disease progression and response to antirefiltration therapy.
The LancetDetection of diverse HIV-1 genetic subtypes in the USA
134 Citations1995Stephanie K. Brodine, Frank C. Garland +7 more
The dispersal of diverse HIV-1 subtypes into regions of the world with previously restricted genetic diversity may have important implications for the epidemiology of the epidemic and for the design and implementation of vaccine trials.
Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5.
133 Citations1998Mark B. Feinberg, Jonathan E. Kaplan
Journal of Clinical MicrobiologyEfficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1
133 Citations1999Karine Triques, J. Coste +10 more
The AMPLICOR HIV-1 MONITOR Test, version 1.5, yielded accurate measurement of the HIV load for all HIV- 1 subtypes tested, which should allow the test to be used to assess disease prognosis and response to antiretroviral treatment in patients infected with a group M HIV-2 subtype.
Journal of Clinical MicrobiologyDevelopment of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes
129 Citations1999Nelson L. Michael, Steven A. Herman +12 more
The AMPLICOR HIV-1 MONITOR Test, version 1.5 is described, an upgraded test developed to minimize subtype-related variation and standardization of PCR-based tests against well-characterized viral isolates representing the full range of HIV- 1 diversity will be essential for the continued utility of these important clinical management tools.
AIDS Research and Human RetrovirusesImpact of HIV Type 1 Subtype Variation on Viral RNA Quantitation
126 Citations1999Bharat Parekh, Susan Phillips +4 more
The addition of a new primer set, designed for non-B HIV-1 subtypes, to the existing MONITOR assay resulted in RNA detection in all 60 specimens and significantly improved the efficiency of quantitation for subtypes A and E.
AIDSMost HIV-1 genetic subtypes have entered Sweden
116 Citations1997Annette Alaeus, Thomas Leitner +2 more
The complete dominance of subtype-B infections which was seen during the early phase of the HIV-1 epidemic in Europe and the US has been broken in Sweden.
VirologyBiological and Molecular Characterization of Subtype D, G, and A/D Recombinant HIV-1 Transmissions in Sweden
114 Citations1995Thomas Leitner, D Escanilla +6 more
This study demonstrates that HIV-1 variants of subtypes other than B, including a subtype A/D recombinant, are being transmitted in Europe and suggested that the correlation between biological phenotype and V3 genotype that has been established for subtype B HIV- 1 variants may be valid also for other subtypes.
Journal of Medical VirologyComparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma
106 Citations1996Joliette Coste, Brigitte Montès +6 more
Quantitation of HIV‐1 RNA in culture supernatants from HIV‐ 1 subtype A to H strains showed that bDNA can be used to quantitate RNA from all HIV‐2 subtypes, whereas Amplicor failed to detect RNA from subtype B strains and NASBA subtype G strains.
Annals of Internal MedicineDrug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion
103 Citations1999Stephanie K. Brodine, Richard A. Shaffer +11 more
The prevalence of non-subtype B infection and genotypes associated with antiretroviral drug resistance in a well-characterized cohort of military personnel with recently acquired HIV-1 infection is determined.
Frontiers research topicsHIV-1 Genetic Diversity
89 Citations2021Francine E. McCutchan, Mika Salminen +2 more
Journal of Clinical MicrobiologyDeterminations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome
86 Citations1998Judy Lew, P S Reichelderfer +23 more
A growing number of adult and pediatric studies have demonstrated that human immunodeficiency virus (HIV) type 1 (Hiv-1) RNA levels have importance in determining the risk of both disease progression and the transmission of infection from mother to infant.
Journal of Clinical MicrobiologyClinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma
81 Citations1998Frederick S. Nolte, Jodi Boysza +3 more
The performance characteristics of an enhanced-sensitivity branched-DNA assay (bDNA) and a reverse transcription (RT)-PCR assay (RT-PCR) were compared in a molecular diagnostic laboratory and one non-B subtype was recognized in clinical specimens based on the ratio of values obtained with the two methods.
AIDS Research and Human RetrovirusesFailure to Quantify Viral Load with Two of the Three Commercial Methods in a Pregnant Woman Harboring an HIV Type 1 Subtype G Strain
65 Citations1998Zeger Debyser, Eric Van Wijngaerden +6 more
To the authors' knowledge this is the first report of a patient harboring an HIV-1 genotype of the main group with a high viral load as quantified by the branched DNA assay, but undetectable with the two commercial HIV RNA amplification techniques because of genetic divergence.
Journal of Acquired Immune Deficiency Syndromes & Human RetrovirologyIntermediate-Size Trials for the Evaluation of HIV Vaccine Candidates: A Workshop Summary
57 Citations1997Wasima Rida, Patricia Fast +2 more
Intermediate-size trials are proposed as a method for assessing the plausibility that a vaccine candidate would prevent chronic HIV infection and could contribute significantly to HIV vaccine development.
Journal of Clinical MicrobiologyAbsolute Copy Number and Relative Change in Determinations of Human Immunodeficiency Virus Type 1 RNA in Plasma: Effect of an External Standard on Kit Comparisons
51 Citations1998Donald Brambilla, Sheila Leung +12 more
Use of a common set of human immunodeficiency virus type 1 (HIV-1) RNA standards eliminated differences among absolute HIV-1 RNA copy number estimates made with three commercially available assays.
Journal of Clinical MicrobiologyDesign and Evaluation of a Human Immunodeficiency Virus Type 1 RNA Assay Using Nucleic Acid Sequence-Based Amplification Technology Able To Quantify Both Group M and O Viruses by Using the Long Terminal Repeat as Target
39 Citations1999Michel P. de Baar, Audrey M. van der Schoot +7 more
Qualitative assays based on nucleic acid sequence-based amplification (NASBA) technology, with primers and probes located in the conserved long terminal repeat (LTR) region of the HIV-1 genome, are developed and evaluated, indicating that LTR-based assays, including the NASBA format chosen here, are better suited to monitoring HIV- 1 therapy than aregag-based Assays.
PubMedTrial objectives and end points for measuring the efficacy of HIV vaccines.
11 Citations1995Rodney Hoff, L. F. Barker
In order to prove the efficacy of human immunodeficiency virus (HIV) vaccines, it will be necessary to do large-scale trials in populations at high risk of acquiring HIV infection, where the objective of preventing the establishment of chronic infection is a reasonable choice.